Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Research Site Leipzig, Permoserstrasse 15, 04318, Leipzig, Germany.
Sci Rep. 2019 Dec 11;9(1):18890. doi: 10.1038/s41598-019-55354-w.
Monocarboxylate transporters 1 and 4 (MCT1 and MCT4) are involved in tumour development and progression. Their level of expression is particularly upregulated in glycolytic cancer cells and accordingly MCTs are considered as promising drug targets for treatment of a variety of human cancers. The non-invasive imaging of these transporters in cancer patients via positron emission tomography (PET) is regarded to be valuable for the monitoring of therapeutic effects of MCT inhibitors. Recently, we developed the first F-radiolabelled MCT1/MCT4 inhibitor [F]FACH and reported on a two-step one-pot radiosynthesis procedure. We herein describe now a unique one-step radiosynthesis of this radiotracer which is based on the approach of using a methylsulfonate (mesylate) precursor bearing an unprotected carboxylic acid function. With the new procedure unexpected high radiochemical yields of 43 ± 8% at the end of the radiosynthesis could be obtained in a strongly reduced total synthesis time. Moreover, the radiosynthesis was successfully transferred to a TRACERlab FX2 N synthesis module ready for future preclinical applications of [F]FACH.
单羧酸转运蛋白 1 和 4(MCT1 和 MCT4)参与肿瘤的发生和发展。它们的表达水平在糖酵解癌细胞中特别上调,因此 MCT 被认为是治疗多种人类癌症的有前途的药物靶点。通过正电子发射断层扫描(PET)对癌症患者这些转运蛋白进行非侵入性成像,被认为对监测 MCT 抑制剂的治疗效果有价值。最近,我们开发了第一个 F-放射性标记的 MCT1/MCT4 抑制剂 [F]FACH,并报告了两步一步一锅法的放射性合成过程。我们现在描述了一种基于使用带有未保护羧酸功能的甲基磺酸酯(甲磺酸盐)前体的独特一步放射性合成方法。采用新方法,在大大缩短总合成时间的情况下,可在放射性合成结束时获得 43±8%的出乎意料的高放射化学产率。此外,该放射性合成已成功转移到 TRACERlab FX2 N 合成模块,为 [F]FACH 的未来临床前应用做好了准备。